Since having been observed and then clearly described by Delay and Deniker (6, 7, 8) , the neurological effects produced by neuroleptic drugs have constantly given rise to various interpretations. Works on this subject can be arbitrarily divided into two categories: on the one hand, those dealing with the neurophysiological nature of extrapyramidal phenomena and on the other, those, much less numerous, which study its psychodynamic or psychoanalytical aspect.
Our purpose here is not to consider the etiophysiological problem resulting from the neuropsychic manifestations produced by psychotropic drugs. However, for a better understanding of what follows, a brief summary of the various opinions expressed on this subject must be gIven.
Some believe that the extrapyramidal syndrome is a condition necessary to therapeutic activity (16, 17, 21, 37) . This theory, prompted by the simultaneous occurrence of excellent therapeutic results and the existence of extrapyramidal symptomatology, has now but few followers, at least as it was originally formulated. Delay and Deniker (9) thus very rightly observe that extrapyramidal syndromes include symptoms which, chronologically overlap or not, according to the patient, the dosage and the drug taken, and which cannot be considered as having the same value.
Both investigators claim that to dissociate the akinetic syndrome from the sedative action would seem difficult, and that the hyperkinetic syndrome is related to a disinhibitory action. Haase (22, 23, 24) , on the evidence of the micrography of patients treated by neuroleptic drugs, considers akinesia as an indispensable condition of therapeutic efficacy.°D irecteur, Service de Recherches, Centre Psychiatrique de [oliette, P.Q. Sigwald (36) , Freyhan (20, 18) , Lambert and Brousolle (26), Divry, Bobon and Collard ( 15) believe that neurological semiology makes it possible to predict the efficacy of neuroleptics, and that it is useful as an index of drug saturation but that its systematic appearance is by no means of primary importance.
Very few among the works we have just considered take into account the patient 'experiencing" these symptoms. Gratton (21) merely points out that patients tolerate the hyperkinetic disorders with difficulty. Freyhan (19) , in discussing the end result of neuroleptic treatment on the psyche, writes: "Whether or not such a temperamental transformation serves a therapeutic purpose depends as much on the kind of psychopathological symptoms as on their meaning. Patients' experiential reactions to drugs are highly individual". Bente (4) says roughly the same thing: "... every psychophysical effect is experienced according to the personality subjected to this effect". Further on, we shall come back to these remarks and expand on them.
The opinions of those who have looked into the problem of side effects from the psychopathological point of view, also differ. Some clinicians, such as Arnold (1) and Winkelmann (38) , find that their appearance is due to the economical reorganization of pulsionnal energies, which, according to Azima (2) , are under the chemical action of the drug. Others, such as Denber (12) and Sarwer-Foner (35) , admit that, in the great majority of cases, the nature of adventitious symptoms is organically determined, but they are primarily interested in studying the way in which patients 'experience' them 'The English word does not fully render the meaning of what is meant here. It corresponds in French to 'le vecu' and in German to 'das Erleben", -consciously and unconsciously; and this is what we should like to do now.
Since we shall have to take what will seem a theoretical position in suggesting the use of corrective medication, we should first like to give a brief account of our empirical line of conduct, in the light of the arguments mentioned above. We must first repeat, with Delay and Deniker (9) , that" ... as far as our knowledge goes, there seems to be a relation between the somatic and psychic effects, but the nature of this relation cannot yet be defined". We must also add what daily experience teaches us: that, in general, correction of side effects by the use of anti-Parkinson drugs, or any others: does not hinder the therapeutic efficacy of neuroleptic drugs (12, 25, 28, 36) . We do not, however, underestimate the real substance of the problem, which although better defined, remains a moot point; for as far as we know, there has never been a double-blind comparative study made which would associate the simultaneous or separate taking of anti-Parkinson and neuroleptic drugs, while carefully noting, by means of objective tests, the appearance of secondary symptoms that would be compared later to the rate and quality of the patients' remission.
Material and Methods
This report deals with clinical experience acquired while observing patients under treatment, either with usual neuroleptics or with new drugs being clinically tested.
The method followed simply consisted of a careful, non-directive questioning of every patient as to what he felt while experiencing such and such side effects. At first he was asked to give a precise description of them and had then to say if his feelings were pleasant; unpleasant, or indifferent, how so and why. Using Denber's technique, they were also asked the following questions: "Have you already had this feeling before? Does it "The reader is referred to Michel Perier's thesis (29) , which covers exhaustively all drugs employed to correct the different neuroleptic-induced neurological symptoms. remind you of anything?" In many cases, patients were unable to describe their symptoms other than by saying: "It's unpleasant ... it makes me feel nervous ... I can't sit still ... I can't work ... I feel slowed down .. I feel sleepy".
Our experimental group is made up of newly admitted patients, a large number of chronic patients, as well as patients regularly seen during their follow-up. They all belonged to the state hospital of a large American city or to a European university clinic". The following observations are strictly limited to the appearance of the side effects produced by neuroleptic drugs when taken by schizophrenics.
By side effects, are meant all the manifestations described in the sequelae of Von Economo's encephalitis, usually called 'extrapyramidal syndrome'. It has already been noted how lacking in precision this term was and, like Delay and Deniker, we shall make a distinction in this study between, a) the akinetic syndrome, added to which will be somnolence and asthenia, since they are clinically difficult to dissociate; b) the akinetohypertonic syndrome; and c) the hyper. kineto-hypertonic syndrome, added to which will be the paroxystic hypertonic phenomena, although they usually appear in the early sta:ge of the treatment'. For each of these phases, which actually often overlap, we shall briefly mention the therapeutic measures indicated in the frame of our own clinical experience.
In addition to the actual instantaneous somatic experiences connected with the neurological syndromes of neuroleptics, their remote psychological impact, which is far from negligible, will be discussed. In spite of their frequency, the neurovegetative side effects will not be dealt with because their psychodynamic implications-although exceptions do existare less important than the ones provoked 'For a detailed description of these syndromes, cf. the works of the same authors (6, 7, 8, 10) . August, 1964 SIDE EFFECTS OF NEUROLEPTICS 347 by motor symptoms, since the vegetative symptoms are devoid of the latter's novel and dramatic nature.
Clinical Observations

Akinetic Syndrome
With the akinetic syndrome, the clinician certainly finds himself faced with one of the most difficult problems in the use of neuroleptics; firstly, because its manifes~ations do appear insidiously, are often difficult to objectivate clinically, and are not easy to correct with anti-Parkinson drugs; secondly, because as Conte (5) brings out, "symptoms having a psychomotor aspect (akinesia with loss of kinetic initiative, simultaneous modifications of psychic and motor time ...) are nearer to personality ..."
This syndrome provokes disturbances which are experienced in a different way in the case of chronic schizophrenics and of those whose illness is recent (or has not become chronic). In the first case, a 'syndrome d'indifference', as Balvet (3) has termed it, may occur, with a coarctation of interest in the environment, lack of initiative, and complacent satisfaction with the hospital routine. Rare in the cases we observed, this state seems rather o superimpose itself on an already exist-Ing symptomatology and gives evidence of a therapeutic failure. In most cases, h0.we~er; and even with chronic patients akinesia IS tolerated with great difficulty. When carefully questioned, patients always complain about being 'different', 'slo.wed down', 'changed". Two of our patIents, one a very inteHigent nurse, declared, after having knowingly discontinued their treatment, that they preferred to be ill for a few weeks, in order to "be themselves again".
The consequence is that patients use every means not to take their medication" and frequently discontinue their followup treatment, more especially since few 5Are these experiences to be connected with a transformation of perceptual experiences at the level of the r<:t.cul.ar substance which w?uld 'filter' the incoming st.mu~t~much, while the Illness would overflow this sensorial impulse regulator? ( 27) Clinical experience would seem to substantiate this theory but no proof of it has yet been given. ' among them, as we have pointed out elsewhere (32) , can establish a cause and effect relation between improvement and drug therapy. The discovery of piperazine compounds and butyrophenones has entailed the attenuation and sometimes the sup-press~on of the. akinetic sy~ptomatology and ItS pSYChIC accompamment, while safeguarding and often improving the therapeutic results obtained with chlorpromazine. But these cases are exceptional, and the physician must not overlook the importance of his patient's complaints.
In the hospital, when the patient's clinical state requires high dosage, in such a way that the side effects cannot be completely' eliminated, a few psychotherapeutically oriented explanations are often sufficient to dispel or at least diminish the anxiety linked to those sidẽ ffects. Sometimes, the patient who has Just gone through paroxysms of psychotic anguish welcomes this 'chemical ?amping'. It nearly always happens dur-109 the drug induction period, and corrective agents must not then be employed.
We have never observed an increase of anxiety during the akinetic phase, as Sarwer-Foner pointed out (34) . We have only witnessed stubborn anxieties which actually increased with the dosage. This kind of anxiety, however, completely vanished with the appearance of a hypertonic or hyperkinetic syndrome corrected by anti-Parkison drugs. It may be assumed that in these cases the therapeutic level was reached only above the akinetic phase.
During the follow-up, everything must be done to eliminate these side effects, otherwise the patient may stop his treatment. One dose, one or two hours before bedtime, gave excellent results. In about two-thirds of the cases, one anti-Parkin-·We noticed this in the hospital wards of three different countries (the U.S.A., France, and Gennany). Tht:refore, no cultural differences are at work here. A patient has shown us the various 'tricks' used to evade the nurses' vigilance. It is rather surprising not to find this 'variable' mentioned in psychiatric literature. Vol. 9, No.4 son tablet on awakening was enough to suppress the somnolence and sluggishness the patients were complaining about.
There is nothing paradoxical about the anti-akinetic and stimulating effect of anti-Parkinson drugs, for their effect has often been related to their anticholinergic action, which, according to Rinaldi and Himwich (32) , takes place within the reticular activating substance. To substantiate this data, there is the striking example of a patient who, after having taken two tablets of 30 mg. of prochlorperazine per day, fell into a state close to narcolepsy: she was sleeping from 15 to 18 hours a day. Procyclidine, 5 mg. b.i.d., was sufficient to eliminate this somnolence completely.
The Akineto-Hypertonic Syndrome
This syndrome which produces, so to speak, a chemical strait-jacket, yet without attacking the patient's dignity, gave us the opportunity of making some interesting observations. For example, an aggressive patient with dangerous impulses, felt relieved and calmed down, in spite of the fact that she was rigid to the point she could hardly move. A nurse, touched by her state, took the initiative of giving her an anti-Parkinson tablet. One hour Iater the patient asked for a strait jacket, for she felt that she was going to lose control of herself. This antitherapeutic effect might be ascribed to the direct chemical effect of the anti-Parkinson drug, but it would mean that anti-Parkinson drugs have always the same results, which is not so. Akinesia and hypertony would seem, in the example given, to have been combined with the patient's psychopathology and temporarily served as a protection against impulses which overwhelmed her, in the same way as we see agitated patients calm down once they have been put into the strait-jacket", Further proof is offered by the same patient who, 15 days later, as she~as no longer hallucinating, started "Racamier (31) gives a detailed explanation. of the psychodynamic mechanisms of this apparently paradoxical reaction.
to complain about symptoms which had not bothered her up until then. This time, corrective medication, far from being noxious, improved the patient's efficiency at work.
By and large, the akineto-hypertonic syndrome is as badly tolerated as the akinetic syndrome, and corrective agents are necessary whenever it proves to be experienced with anxiety.
The Hyperkineto-Hypertonic
Syndrome and the Paroxystic H yperkynesias Individuals or groups of patients react in totally different ways to these somatic experiences, which require just as varied therapeutic measures. Many chronic patients who were, up until then, perfectly isolated in their autism and adapted to hospital life, avoiding and discouraging any contact with surprising trickery, suddenly see their way of life threatened by the appearance of anxiety linked to akarhisia, trembling, oculogyric crises, etc. They turn for help and assistance to the medical staff and nurses. This is the moment not to miss, for it makes possible the initiation of a psychotherapeutic relationship.
If the patient is simply sent away with or without corrective medication but with no effort having been made to establish a psychotherapeutic rapport, the quality of a possible remission is in jeopardy. In the first place, the patient will probably go back to his isolation, even if he is cured from his hallucinatory syndrome; for, if chemotherapy makes resocialization easier, it has no direct effects on the process, which functions through interpersonal relations. Moreover, the patient will be strengthened in his opinion that "people are bad", because they inflict such torture upon him. He will thus take the first opportunity to stop taking his tablets, which are identified with the unhelpful physician.
If, on the contrary, in the case of supervening hyperkinetic disorders, the psychiatrist can prove to the patient that August, 1964 SIDE EFFECTS OF NEUROLEPTICS 349 there exist good objects-that is, the physician, and through him, the drugthe patient may be put on the road to resocialization. The best way to achieve this is to relieve the patient of the painful side effects he experiences.
It is, however, sometimes necessary to discontinue anti-Parkinson medication in order to bring the patient back to his doctor, in case he would be tempted to go back to his autism and evade again all contacts.
Things are somewhat different with non-chronic schizophrenics, who usually experience hyperkinetic symptoms with great anxiety, sometimes even with such panic as to lead them to suicide. Since these patients do not avoid contact with the nursing staff -indeed they seek it out -they must be spared the anxiety provoked by the appearance of hyperkinetic phenomena, probably experienced by them as a threat to their already shattered self-image.
The Remote Impact of Side Effects
Thus far, we have mainly been concerned with the actual, instantaneous psychological effects of somatic experiences linked to neuroleptic medication. Their remote impact -that is, the impact during the after-care -turns out to be quite as important and has, to our knowledge, been observed only by Sarwer-Foner (35) . Why do psychotic patients so often discontinue their followup treatment, frequently leading to a relapse and rehospitalization? (32) The answer is not simple, and it is not within the scope of this paper to deal with the problem. However two most important and interdependent causes can be stated as follows:
a) The great majority of schizophrenics are incapable of establishing a cause and effect relation between the absorption of a . drug and their improvement, this in spite of the repeated assurances they give the psychiatrist for fear of displeasing him. b) Any disagreeable stimulus connected with the taking of a drug will provoke an avoidance-reaction, and any agreeable stimulus will facilitate its acceptance. In terms of psychodynamics, the medication is assimilated to the total complex of circumstances that occurred during the taking of it in hospital. Among these, the physician stands out because of his prominent position, but also to be taken into account are the behaviour of the medical staff, the side effects, etc. In this respect, 'les crises excito-motrices' and the tonic spasms have particularly nociceptive properties. It suffices to mention the name of a phenothiazine to patients who have received this drug during the first clinical trials in which they did not take anti-Parkinson drugs, to see them categorically refuse to take it again, even were it the drug that proproduced a remission, and it is with great difficulty that they agree to take another neuroleptic. On the other hand, three of our former patients", who have been in perfect remission for over four years, come regularly to the ward to get this drug, because they have never felt any severe side effect.
The discontinuous therapy proposed by some European researchers (8) has, in this perspective, the disadvantage of an 'intermittent deconditioning' and is not advisable, more especially since its advantages over a continuous treatment have not been proved (14, 30) .
Summary
It has been pointed out above that every side effect produced by neuroleptics is invested with a psychodynamic significance in relation to the evolution of the psychosis. This side effect can, independently from its neurobiochemical cause, momentaneously act in a favourable when he took the drug, for schizophrenics can generally establish no cause and effect relation between the absorption of a drug and their improvement.
It is therefore important to assess, for every patient, the way in which he experiences side effects at different stages of the treatment, in order to correct them or not, according to whether they are psychologically noxious or beneficial.
This empirical line is defensible on the grounds that a review of the various viewpoints now prevailing on the role of neurologic symptoms provoked by neuroleptics, shows that there is no agreement on their therapeutic value and that everyone tries, in fact, to correct them without compromising the efficacy of these drugs.
Resume
Nous avons fait remarquer que chaque effet secondaire produit par les neuroleptiques s'investit d'une signification psychodynamique variable suivant l'evolution de la psychose. Cet effet secondaire peut, independamment de sa cause neurobiochimique, agir momentanernent d'une maniere favorable ou de£avorable sur le cours de la maladie. De plus, l'attitude du malade durant la post-cure sera conditionnee par les experiences concomitantes a la prise du medicament, car les schizophrenes savent rarement etablir une relation de cause a effet entre l'absorbtion d'un medicament et leur amelioration.
II est done tres important d'evaluer, pour chaque patient, Ie facon dont il 'vit' les effets secondaires adifferents moments du traitement afin de les corriger ou non, suivant qu'ils peuvent etre responsables de repercussions psychologiques nuisibles ou benefiques.
Cette Iigne de conduite empirique nous parait legitime, car une revue des differentes opinions ayant cours sur Ie role des symptomes neurologiques induits par les neuroleptiques, montre qu'il n'existe aucun accord sur leur valeur therapeutique et qu'en pratique, chacun s'emploie ales corriger sans compromettre l'efficacite de ces medicaments.
